TrialHaematologica2022

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial.

Francesco Buccisano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.